Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycerol phenylbutyrate - Horizon Therapeutics plc

Drug Profile

Glycerol phenylbutyrate - Horizon Therapeutics plc

Alternative Names: GT4P; HPN-100; Ravicti

Latest Information Update: 16 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ucyclyd Pharma
  • Developer Horizon Pharma; Horizon Therapeutics plc; National Jewish Health
  • Class Hepatoprotectants; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Hepatic encephalopathy; Spinal muscular atrophy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Inborn urea cycle disorders
  • Phase I/II Cystic fibrosis
  • No development reported Hepatic encephalopathy

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 27 Dec 2018 Registered for Inborn urea cycle disorders (In infants, In neonates) in USA (PO)
  • 18 Dec 2018 Registered for Inborn urea cycle disorders (Adjunctive treatment, In adolescents, In children, In infants, In adults, In neonates) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top